Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Sponsors
Bristol Myers Squibb International Corporation, AstraZeneca AB, 1globe Health Institute LLC
Conditions
Advanced/Metastatic Gastric cancerBiliary Tract CancerGastric CancerGastric cancerGastroesophageal Junction Adenocarcinoma Expressing Claudin18.2Gastroesophageal Junction CancerHistologically confirmed adenocarcinoma of the colon or rectum that is metastatic.Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient
Metastatic Colorectal Cancer (dMMR)
Phase 1
Phase 3
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
Active, not recruitingCTIS2023-503956-29-00
Start: 2019-08-26Target: 571Updated: 2025-12-15
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin 18.2 (CLARITY-Gastric 01)
RecruitingCTIS2023-508276-11-00
Start: 2025-01-17Target: 91Updated: 2025-09-15
A Phase III, Randomized, Open-Label Clinical Study of Napabucasin in Combination with FOLFIRI and Best Supportive Care (BSC) Versus Napabucasin plus BSC in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
Active, not recruitingCTIS2024-518204-50-00
Start: 2022-04-25Target: 123Updated: 2025-12-10